🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. Cytarabine

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  2. Cytarabine (Phase 1 only)

    Actinium Pharmaceuticals

    AML

    phase 2 small molecule completed

    1 trial

  3. Cytarabine and Idarubicin

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  4. DA-302168S

    Chendu DIAO Pharmaceutical Group CO., LTD.

    Overweight and Obesity

    phase 2 small molecule active

    1 trial

  5. DANAZOL , -, -, -, ENTECAVIR , -, VAY736

    Novartis Pharmaceuticals

    Immune thrombocytopenia (ITP) Warm autoimmune hemolytic anemia (wAIHA)

    phase 2 small molecule active

    1 trial

  6. DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Empliciti 400 mg powder for concentrate for solution for infusion., Dexamethason CF 20 mg/ml, injectievloeistof, Dexamethasone 2mg Tablets, VELCADE 3.5 mg powder for solution for injection, DARZALEX 1800 mg solution for injection, Dexamethason 4 mg JENAPHARM®, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, CC-92480, CC-92480

    Celgene Europe Limited

    Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)

    phase 2 small molecule active

    1 trial

  7. DB-OTO

    Lacuna Pharma Pty Ltd

    Congenital Hearing Loss Secondary to Biallelic Pathogenic Variants of the Otoferlin Gene (OTOF)

    phase 2 small molecule active

    1 trial

  8. DCC-3014, DCC-3014, DCC-3014

    Lacuna Pharma Pty Ltd

    Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    phase 2 small molecule active

    1 trial

  9. DCC-3084, DCC-3084

    Lacuna Pharma Pty Ltd

    Solid tumors driven by the MAPK Pathway

    phase 2 small molecule active

    1 trial

  10. DEGARELIX ACETATE, ENZALUTAMIDE, DEGARELIX, ENZALUTAMIDE, DAROLUTAMIDE, RELUGOLIX, -, ENZALUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, Pluvicto 1 000 MBq/mL solution for injection/infusion, APALUTAMIDE

    Novartis Pharmaceuticals

    PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)

    phase 2 small molecule active

    1 trial

  11. DEGARELIX, -, RELUGOLIX, ABIRATERONE, DEGARELIX, Luxdegalutamide, ABIRATERONE, ABIRATERONE, Abiraterone, ENZALUTAMIDE, ABIRATERONE, Enzalutamide

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  12. DEXAMETHASONE, CARFILZOMIB, DEXAMETHASONE, DEXAMETHASONE, CC-92480

    Pari Pharma GmbH

    Patients with relapsed/refractory symptomatic multiple myeloma (MM)

    phase 2 small molecule active

    1 trial

  13. DFV890, DFV890, Placebo to MAS825 100 mg/1 mL Solution for Injection, Placebo to DFV890 10 mg and 25 mg film-coated tablet, MAS825

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease

    phase 2 small molecule active

    1 trial

  14. DIMETHYL FUMARATE, DIMETHYL FUMARATE

    Pari Pharma GmbH

    Macular degeneration

    phase 2 small molecule active

    1 trial

  15. DNS-6288, DNS-6288

    Lacuna Pharma Pty Ltd

    Catecholaminergic Polymorphic Ventricular Tachycardia

    phase 2 small molecule active

    1 trial

  16. DONEPEZIL ARROW 5 mg, comprimé pelliculé, The placebo has the same container composition as the investigational medicinal product (exception of the active substance) and is manufactured by the same manufacturer (pui of the brest university hospital) according to the same procedures as the investigational medicinal product. the active substance is lactose monohydrate, ARICEPT 5 mg, comprimé pelliculé, DONEPEZIL BIOGARAN 5 mg, comprimé pelliculé

    Pari Pharma GmbH

    Anorexia nervosa

    phase 2 small molecule active

    1 trial

  17. DR-1031

    Teva Pharma GmbH

    Breakthrough Bleeding

    phase 2 small molecule completed

    1 trial

  18. DR-2001a

    Teva Pharma GmbH

    Endometriosis

    phase 2 small molecule completed

    1 trial

  19. DR-2021a

    Teva Pharma GmbH

    Amenorrhea

    phase 2 small molecule completed

    1 trial

  20. DR-3001a

    Teva Pharma GmbH

    Urinary Incontinence

    phase 2 small molecule completed

    1 trial

  21. DSM265

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule terminated

    2 trials

  22. DYP688

    Novartis Pharmaceuticals

    Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)

    phase 2 small molecule active

    1 trial

  23. DZR123, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  24. Dabrafenib

    Novartis Pharmaceuticals

    Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources